Hyaluronic acid maker Bloomage Biotech (华熙生物) cut its selling expenses further to 31.79 percent of revenue in the third quarter, according to its 2026 third-quarter report dated 29 October. Revenue for July to September slipped 6.96 percent to RMB 839.84 million, yet net profit attributable to shareholders edged up 5.62 percent.
Lower costs pushed quarterly profit up despite weaker sales
Net profit attributable to shareholders reached RMB 33.30 million in the third quarter. Stripping out non-recurring items, it rose 165.00 percent to RMB 30.99 million, which Bloomage put down mainly to a leaner business structure and tight control of spending.
Total profit for the quarter grew 20.03 percent to RMB 37.46 million. Basic earnings per share held at RMB 0.07, unchanged from a year earlier; for the nine months they fell 25.00 percent to RMB 0.39. The report describes profitability as improving while revenue stayed under pressure.
Unit: %
Q3 2026, year on year · Source: Bloomage Biotech, 29 October 2026
View as table
| Item | Value |
|---|---|
| Revenue | -6.96% |
| Total profit | 20.03% |
| Net profit to shareholders | 5.62% |
| Net profit excl. non-recurring items | 165.00% |
Nine-month revenue is still down 17.94 percent
The year-to-date picture is weaker. Revenue for January to September fell 17.94 percent to RMB 2.596 billion, and total profit dropped 34.98 percent, mainly because revenue from the skin-science business (皮肤科学创新转化业务) declined.
Net operating cash flow moved the other way, up 87.65 percent to RMB 579.40 million. Bloomage linked this to lower spending and smaller cash payments for goods.
On the balance sheet, contract liabilities stood at RMB 90.56 million at 30 September, up from RMB 57.77 million at the start of the year. Cash and bank balances fell to RMB 824.96 million from RMB 994.98 million.
| Item | Q3 2026 | Change | Jan–Sep 2026 | Change |
|---|---|---|---|---|
| Revenue | 839.84 | -6.96% | 2,596.02 | -17.94% |
| Total profit | 37.46 | 20.03% | 189.54 | -34.98% |
| Net profit to shareholders | 33.30 | 5.62% | 186.09 | -26.27% |
| Net profit excl. non-recurring items | 30.99 | 165.00% | 160.46 | -13.47% |
| Net operating cash flow | 55.22 | -38.93% | 579.40 | 87.65% |
| R&D investment | 112.85 | -13.27% | 324.78 | -10.09% |
Unit: %
January-September 2026, year on year; selling expenses CMB calculation · Source: Bloomage Biotech, 29 October 2026
View as table
| Item | Value |
|---|---|
| Revenue | -17.94% |
| Total profit | -34.98% |
| Net profit to shareholders | -26.27% |
| Net profit excl. non-recurring items | -13.47% |
| Selling expenses | -22.47% |
Selling expenses fell by more than a fifth
Selling expenses for the nine months came to RMB 866.22 million, against RMB 1.117 billion a year earlier. That is a drop of 22.47 percent on a simple calculation, faster than the fall in revenue.
On the same basis, selling expenses took 33.4 percent of nine-month revenue, down from 35.3 percent. The company credits a better brand and channel mix and AI-driven efficiency gains for the lower third-quarter ratio. Administrative expenses also shrank, to RMB 337.58 million from RMB 419.00 million.
R&D investment equalled 13.44 percent of third-quarter revenue and 12.51 percent for the nine months.
Korea’s JUVELOOK joins a new ECM injectable in the medical aesthetics line
In its medical aesthetics business, Bloomage has brought in JUVELOOK from South Korea to widen its regenerative aesthetics (再生医美) range. On 13 October it also launched Runzhi ECM (润致 ECM), a self-developed extracellular matrix injectable.
The company describes the launch as a step from hyaluronic acid towards ECM tissue regeneration. It calls 2026 its “AI year” and says it is applying AI across R&D, manufacturing, supply chain, consumer service and management.
On the raw-materials side, its Bloomsac™ sodium chondroitin sulfate made the global final seven of the Sustainable Pharma Excellence award. Bloomage says it was the only Chinese synthetic-biology company on that shortlist.
